Translating Safer ADCs from Research to Patients

Unravelling ADC Toxicity Mechanisms to Prevent, Predict & Mitigate Safety Risks to Accelerate Translation of Traditional & Novel ADCs Towards Clinical SuccessWelcome to the 3rd ADC Toxicity Summit

As ADC pipelines continue to grow rapidly, toxicity remains one of the biggest barriers to clinical success, patient safety, and regulatory approval. Recent safety setbacks across major ADC programs have intensified industry focus on improving toxicity prediction, translational safety assessment, and dose optimization strategies. Returning in 2026, the 4th ADC Toxicity Summit is the only dedicated industry forum exclusively focused on preventing, predicting, and mitigating ADC toxicities across preclinical and clinical development.

Bringing together toxicologists, translational scientists, pharmacologists, clinicians, and safety leaders from pharma, biotech, and academia, this summit offers a highly focused and collaborative environment to address the industry’s most urgent safety challenges. Across interactive workshops, technical case studies, panel discussions, and networking sessions, attendees will explore advanced in vitro and in vivo models, FDA New Approach Methodologies (NAMs), translational biomarkers, ILD and ocular toxicity management, and safety strategies for next-generation ADCs including dual payloads and bispecifics.

With increased regulatory scrutiny and growing pressure to accelerate safer ADCs to patients, this is the must-attend event for anyone committed to improving ADC tolerability, reducing patient risk, and advancing clinically successful ADC programs.

Download the Agenda

Good selection of speakers and topics, round table discussions truly supported exchange of ideas and experiences

DEM Biopharma

I love hearing perspectives from industry peers regarding the shared challenges we are facing

AbbVie

Small, intimate meeting with leaders in the field and sessions focused on timely and relevant topics

Genentech

Explore the Full Event Guide

Explore fresh scientific perspectives with 25% new speakers and 50% new companies joining the summit in 2026
Learn directly from senior ADC decision-makers, with a speaker faculty made up of 25% C-level and 56% VP/Director-level experts
Build meaningful connections through 10+ hours of dedicated networking, interactive discussion, and collaborative debate
Take part in 2 hands-on workshops designed to tackle translational safety challenges and toxicity mitigation strategies